Methods of using cyclooxygenase-prostacyclin synthase fusion gene

A composition comprising a carrier fluid;

• and a DNA sequence encoding for a triple catalytic enzyme, a cDNA sequence encoding for a triple catalytic enzyme, a plasmid comprising a DNA sequence encoding for a triple catalytic enzyme, a fusion gene encoding for a triple catalytic enzyme, a cyclooxygenase-prostacyclin synthase fusion gene, or combinations thereof, for use in treating an individual having a vascular disease or at risk of developing a vascular disease.

A composition comprising a plasmid comprising a cyclooxygenase-prostacyclin synthase fusion gene, wherein the plasmid comprises a human muscle specific promoter, and phosphate buffer saline, for use in treating an individual having pulmonary arterial hypertension or at risk of developing pulmonary arterial hypertension, wherein the plasmid is present within the composition in an amount of from about 0.4 mg/ml to about 500 mg/ml;

• and wherein the composition is administered via an intramuscular injection into a brachial skeletal muscle.

A composition for prostacyclin (PGI2) delivery, wherein the composition for PGI2 delivery comprises:

• a carrier fluid;
• and a DNA sequence encoding for a triple catalytic enzyme, a cDNA sequence encoding for a triple catalytic enzyme, a plasmid comprising a DNA sequence encoding for a triple catalytic enzyme, a fusion gene encoding for a triple catalytic enzyme, a cyclooxygenase-prostacyclin synthase fusion gene, or combinations thereof.